University of Liverpool Confidence in Concept Program – Enhancing Translation

Lead Research Organisation: University of Liverpool

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

 
Description Clinical Development of an Ultrasensitive OCT Device to Improve the Management of Eye Disease
Amount £1,338,299 (GBP)
Funding ID II-LA-1116-20008 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 11/2017 
End 10/2020
 
Description Development of New Low Cost Point of Care Diagnostic Technologies for Diabetic Retinopathy in China
Amount £1,150,450 (GBP)
Funding ID EP/R014094/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 02/2018 
End 01/2021
 
Description The role of immune tolerance and regulation in pneumococcal carriage and invasive disease.
Amount £1,584,521 (GBP)
Funding ID MR/P011284/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2017 
End 05/2022
 
Title CANCER TREATMENT 
Description Provided is the use of inactivated FABP5 proteins, or fragments or variants thereof, as a medicament. These may be used in the treatment of a FABP5 mediated disorders, such as cancer. The inactivated FABP5 proteins, or fragments or variants thereof, may also be used in therapeutically reducing PPARY activation. The treatments of the invention are particularly useful in treating prostate cancer, and in inhibiting metastasis associated with this disease. A suitable inactivated FABP5 protein, or fragment or variant thereof, may incorporate mutations in amino acid residues associated with long chain fatty acid binding, such as Arg 109 and/or Arg 129. 
IP Reference WO2017103625 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Translational grant; Chinese Govt; £120K
 
Title MUSCLE REGENERATION 
Description The invention provides anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitorfor use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cellregeneration. Byprotecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres. 
IP Reference WO2017194975 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact we are developing talks with a pharma company that specialises in the development of therapies for DMD (Solid Biosciences).
 
Title OPTICAL INTERFEROMETRY APPARATUS AND METHOD 
Description Embodiments of the present invention provide a method and apparatus for frequency-domain optical interferometry imaging. Embodiments of the invention include an apparatus comprising a line- shaping optical element for directing optical radiation into a line illumination, an imaging optical element for receiving optical radiation comprising radiation reflected from a target sample and a reference point associated with the target sample,and a detection unit for measuring common path interferences between a plurality of reflections from the target sample and the reference point. Embodiments of the invention include a method comprising directing radiation into a line illumination, directing the line illumination towards a target sample, receiving radiation reflected from the target sample at a detection unit,and measuring common path interferences between a plurality of reflections at the target sample and a reference point. 
IP Reference WO2017168181 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Novel OCT instrumentation was designed and built with promising performance for future clinical benefit. New software programs were developed to operate the new OCT device and support data acquisition and image analysis for accurately computing lens power.
 
Title PHARMACOLOGICALLY ACTIVE COMPOUNDS 
Description wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them. 
IP Reference US2019084993 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact The project created valuable IP (category: Composition-of-Matter, newly synthesised compounds) which is exclusively owned by the University of Liverpool. US patent (No. 9676786) as well as European patent (No. 3087055) have been granted. We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor.